<!DOCTYPE html>


<style>
    body{
  background: #18181B;
}

.main{
  font-family: "Noto Sans", ui-sans-serif, system-ui, -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Noto Color Emoji";
  color: #FDFDFD;
}

h1 {
  font-size: 2.5rem;
  color: white;
}

h3 {
  font-size: 1.5rem;
  background: #0c087c;
  padding: 10px;
  margin: 0px;
  border: 1px solid #6b7280;}

.extended-title{
  width:100%;
}

#gsk-overview{
  display:flex;
}

h4 {
  font-size: 1rem;
  background: #27272A;
  padding: 10px;
  margin: 0px;
  border-bottom: 1px solid #6b7280;
}

h2 {
  font-size: 1.5rem;
  margin-top: 3px;
  color:#000000;
}

.header{
  display: flex;
  justify-content: center;
  align-items: center;
}
.header > * {
  margin-inline: 20px;
}

.flex-row {
  display: flex;
  flex-direction: row;
  padding:10px;
  border: 1px solid #27272A;
}

.flex-row>div {
  flex: auto;
  box-sizing: border-box;
  display: flex;
  flex-direction: column;
  justify-content: center;
  align-items: center;
}

progress[value] {
  --background: #6D6D6D;
  -webkit-appearance: none;
  -moz-appearance: none;
  appearance: none;
  border: none;
  height: 4px;
  margin: 0 10px;
  border-radius: 10em;
  background: var(--background);
}

progress[value]::-webkit-progress-bar {
  border-radius: 10em;
  background: var(--background);
}

progress[value]::-webkit-progress-value {
  border-radius: 10em;
  background: var(--color);
}

progress[value]::-moz-progress-bar {
  border-radius: 10em;
  background: var(--color);
}

label {
  font-size: 20px;
  font-weight: bold;
  display: block;
  margin: 20px 0;
}

.tab {
  overflow: hidden;
  border: 1px solid #27272A;
  background-color: #27272A;
}

.tab button {
  background-color: inherit;
  float: left;
  border: none;
  outline: none;
  cursor: pointer;
  padding: 14px 16px;
  transition: 0.3s;
  color: #ffffff;
  font-size:1.2rem;
}

.tab div {
  background-color: inherit;
  float: left;
  border: none;
  outline: none;
  cursor: pointer;
  padding: 14px 16px;
  transition: 0.3s;
  color: #ffffff;
  font-size: 1.2rem;
}

.tab button:hover {
  background-color: #18181B;
}

.tab-title{
  font-size: 1.5rem;
  font-weight: bold;
  margin-bottom:-5px;
}

.tab button.active {
  background-color: #18181B;
  border-top: 1px solid #6b7280;
  border-bottom: 1px solid #18181B;
  border-left: 1px solid #6b7280;
  border-right: 1px solid #6b7280;
}

.tabcontent {
  display: none;
  padding: 6px 12px;
  background: #18181B;
  border: 1px solid #27272A;
  border-top: 1px solid #6b7280;
  margin-top: -2px;
}

#gsk-advice {
  display: flex;
  justify-content: center;
}

#gsk-metrics{
  width:100%;
}

#recommendation {
  margin-top: 20px;
  padding: 20px;
  border-radius: 10px;
  background-color: #e1ce86;
  color: #27272A;
  width:95%;
  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;
  font-size: 12pt;
}

.separator {
  margin: 20px 0;
}

.separator-border {
  margin: 20px 0;
  border-bottom: 1px solid #6b7280;
}

#gsk-rag{
  margin: 32px 28px;
  padding: 12px 24px;
  background-color: #111516;
}

.section-container {
  margin-bottom: 32px;
}

  .components-container {
    display: flex;
    flex-flow: row wrap;
    align-items: flex-start;
    gap: 0 32px;
  }

    .component-card {
      background-color: #14191B;
      border-radius: 16px;
      padding: 28px 32px 32px 32px;
      display: flex;
      flex-flow: column;
      align-items: center;
      margin-top: 32px;
      flex-grow: 1;
    }

    .component-title {
      font-size: 12px;
      font-weight: 500;
      color: #B1B1B1;
      padding-bottom: 8px;
    }

    .component-value {
      font-size: 32px;
      font-weight: 500;
      padding-bottom: 12px;
    }
      
      .text-green {
        color: #04B543;
      }
      
      .text-orange {
        color: #E76E0F;
      }
      
      .text-red {
        color: #EA3829;
      }

      .tooltip {
        position: relative;
        display: inline-block;
      }

      .tooltip .tooltiptext {
        visibility: hidden;
        width: 120px;
        background-color: #464646;
        color: #E6E6E6;
        text-align: center;
        border-radius: 6px;
        position: absolute;
        z-index: 1;
        top: 150%;
        left: 50%;
        margin-left: -60px;
        font-size: 12px;
        padding: 12px;
      }
      
      .tooltip .tooltiptext::after {
        content: "";
        position: absolute;
        bottom: 100%;
        left: 50%;
        margin-left: -5px;
        border-width: 5px;
        border-style: solid;
        border-color: transparent transparent black transparent;
      }
      
      .tooltip:hover .tooltiptext {
        visibility: visible;
      }

    .overall-card {
      background-color: #026836;
      border-radius: 16px;
      padding: 28px 32px 32px 32px;
      display: flex;
      flex-flow: column;
      align-items: center;
      justify-content: center;
      margin-top: 32px;
      flex-grow: 1;
    }
  
    .overall-title {
      font-size: 12px;
      font-weight: 500;
      color: #E6E6E6;
      padding: 14px 0 8px 0;
      text-transform: uppercase;
     }
  
    .overall-value {
      font-size: 32px;
      font-weight: 500;
      padding-bottom: 12px;
      color: #E6E6E6;
    }

.section-title {
  font-size: 12px;
  color: #B1B1B1;
  margin-bottom: 20px;
  text-align: left;
  width: 100%;
}

.section-content {
  color: #E6E6E6;
  font-size: 20px;
  line-height: 1.5;
}

.section-card {
  background-color: #14191B;
  border-radius: 16px;
  padding: 28px 32px 32px 32px;
  display: flex;
  flex-flow: column;
  align-items: center;
}

.correctness-indicator{
  padding: 20px;
  border-radius: 50px;
  font-size: 16pt;
  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;
  text-align: center;
}

.metric-title{
  margin: -2px;
  border-bottom: none;
}

.hist-row {
  display: flex;
  flex-direction: row;
  padding: 10px;
  justify-content: space-around;
  width: 85%;
}

.hist-row>div {
  flex: auto;
  box-sizing: border-box;
  display: flex;
  flex-direction: column;
  justify-content: center;
  align-items: center;
  padding-left: 1%;
  padding-right: 1%;
}

.tab-row{
  display: flex;
  flex-direction: column;
  align-items: center;
}

#component-table{
  width:50%;
  margin-top: 10px;
}

.green{
  background-color: #0a980a;
}

.orange {
  background-color: #e5b62a;
}

.red {
  background-color: #ba0e0e;
}

.progress-green {
  --color: #04B543;
}

.progress-orange {
  --color: #E76E0F;
}

.progress-red {
  --color: #EA3829;
}

.corr-plot{
  flex: 1;
  padding-left: 2%;
}

.tooltip-text {
  position: absolute;
  display: none;
  visibility: hidden;
  z-index: 1;
  top: 100%;
  left: 0%;
  width: 100%;
  color: white;
  font-size: 12px;
  background-color: #2d3d4c;
  border-radius: 10px;
  padding: 10px 15px 10px 15px;
}

#fade {
  opacity: 1;
  transition: opacity 0.5s;
}

#delay {
  opacity: 0;
  transition: opacity 0.2s;
  transition-delay: 1s;
}

td {
  position: relative;
}

tr:hover .tooltip-text {
  display: block;
  visibility: visible;
}

.tr:hover #fade {
  opacity: 1;
}

.tr:hover #delay {
  opacity: 1;
}

.callout {
  padding: 0.5rem 1rem 0.5rem 3rem;
  background: #D9EDF9;
  border: 3px solid #0088D1;
  color: #272eb5;
  position: relative;
  max-width: 40rem;
  border-radius: 10px;
  margin-top: 10%;
  font-size: 11pt;
}

.callout-icon {
  content: "";

  /* SVG via a data URI! */
  background-size: cover;
  width: 1.5rem;
  height: 1.5rem;
  display: block;
  position: absolute;
  left: 0.9rem;
  top: 1.1rem;
}

.callout-icon svg{
  fill: #016ca7;
}
.callout p+p {
  margin-top: 1em;
}

.callout a {
  color: #272eb5;
  font-weight: bold;
}

#gsk-logo {
  padding-top: 10px;
}
</style>
<script src="https://cdn.bokeh.org/bokeh/release/bokeh-3.3.4.min.js" integrity="sha384-5QIrjQuyo4I/x6DK/Sau33lcA3hT2TCZGr9vbk+2ebd7Da6FnR1amdM+9B5xOrSf" crossorigin="anonymous"></script>
<script src="https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.3.4.min.js" integrity="sha384-tXTWPp/bAKa+K9RPuXh7DNvye0Mv+P+6y4rAMVy+pWapsnXg9UG7g20WZ0N4i28A" crossorigin="anonymous"></script>





<div class="main">
    <div id="gsk-rag" class="dark:text-white dark:bg-zinc-800 rounded border border-gray-500">
        <div class="header border-b border-b-gray-500">
            
                <svg xmlns="http://www.w3.org/2000/svg" width="60" height="30" viewBox="0 0 30 15" fill="none" id="gsk-logo">
                    <path fill="#fff" fill-rule="evenodd"
                        d="M22.504 1.549a4.196 4.196 0 0 1 2.573-.887v.002a3.783 3.783 0 0 1 2.706 1.086 3.783 3.783 0 0 1 1.126 2.69 3.771 3.771 0 0 1-1.126 2.69 3.77 3.77 0 0 1-2.706 1.085l-4.794.011-2.533 3.467L8.203 15l2.881-3.335a9.829 9.829 0 0 1-4.663-1.68H3.185L0 7.163h3.934C4.263 3.165 8.187 0 12.96 0c2.24 0 4.489.696 6.175 1.909a7.423 7.423 0 0 1 1.882 1.919 4.194 4.194 0 0 1 1.487-2.28ZM7.05 3.249l3.91 3.915h1.505L7.89 2.584a7.773 7.773 0 0 0-.84.665Zm4.079-2.008 5.923 5.923h1.503l-6.086-6.087c-.45.023-.898.078-1.34.164ZM4.574 8.226h-1.77l.784.693h1.584a8.454 8.454 0 0 1-.598-.693Zm9.479 0H5.984c1.469 1.477 3.656 2.377 5.977 2.422l2.092-2.422Zm-2.458 4.472 5.492-1.902 1.878-2.569h-3.508l-3.862 4.47Zm10.361-5.552h3.265a2.714 2.714 0 0 0 1.747-4.648 2.711 2.711 0 0 0-1.888-.773 3.127 3.127 0 0 0-3.123 3.124v2.297Zm3.659-3.73a.677.677 0 1 1-.134 1.348.677.677 0 0 1 .134-1.348Z"
                        clip-rule="evenodd" />
                </svg>
            <h1>RAG Evaluation Toolkit</h1>
        </div>
        
        <div class="section-container">
            <div class="components-container">
                
                <div class="component-card">
                    <div class="component-title">GENERATOR</div>
                    <div class="component-value tooltip  text-orange ">
                        44.0%
                            <span class="tooltiptext" id="fade">The Generator is the LLM inside the RAG to generate the answers.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=44.0 class=" progress-orange ">44.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">RETRIEVER</div>
                    <div class="component-value tooltip  text-green ">
                        100.0%
                            <span class="tooltiptext" id="fade">The Retriever fetches relevant documents from the knowledge base according to a user query.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=100.0 class=" progress-green ">100.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">REWRITER</div>
                    <div class="component-value tooltip  text-green ">
                        100.0%
                            <span class="tooltiptext" id="fade">The Rewriter modifies the user query to match a predefined format or to include the context from the chat history.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=100.0 class=" progress-green ">100.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">ROUTING</div>
                    <div class="component-value tooltip  text-green ">
                        100.0%
                            <span class="tooltiptext" id="fade">The Router filters the query of the user based on his intentions (intentions detection).</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=100.0 class=" progress-green ">100.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">KNOWLEDGE_BASE</div>
                    <div class="component-value tooltip  text-green ">
                        100.0%
                            <span class="tooltiptext" id="fade">The knowledge base is the set of documents given to the RAG to generate the answers. Its scores is computed differently from the other components: it is the difference between the maximum and minimum correctness score across all the topics of the knowledge base.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=100.0 class=" progress-green ">100.0%</progress>
                    </div>
                </div>
                
                <div class="overall-card">
                    <div class="overall-title">Overall Correctness Score</div>
                    <div class="overall-value">44%</div>
                </div>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">
                <div class="section-title">RECOMMENDATION</div>
                <span class="section-content">Focus on enhancing the Generator&#39;s performance, particularly for complex questions, as the low score indicates a need for better handling of paraphrased queries. This improvement should help boost the overall capability of your RAG system across the &#34;Others&#34; topic.</span>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">
                <div class="section-title">CORRECTNESS BY TOPIC</div>
                    <script type="text/javascript">
        (function() {
  const fn = function() {
    Bokeh.safely(function() {
      (function(root) {
        function embed_document(root) {
        const docs_json = '{"b058a463-6cca-4faf-b68b-943fe9854835":{"version":"3.4.3","title":"Bokeh Application","roots":[{"type":"object","name":"Figure","id":"p1919","attributes":{"height":350,"width_policy":"max","x_range":{"type":"object","name":"DataRange1d","id":"p1921","attributes":{"start":0}},"y_range":{"type":"object","name":"FactorRange","id":"p1928","attributes":{"factors":["Others"]}},"x_scale":{"type":"object","name":"LinearScale","id":"p1929"},"y_scale":{"type":"object","name":"CategoricalScale","id":"p1930"},"title":{"type":"object","name":"Title","id":"p1926","attributes":{"text_color":"#E0E0E0","text_font":"Helvetica","text_font_size":"14pt"}},"outline_line_color":"#E0E0E0","outline_line_alpha":0.25,"renderers":[{"type":"object","name":"GlyphRenderer","id":"p1948","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p1916","attributes":{"selected":{"type":"object","name":"Selection","id":"p1917","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1918"},"data":{"type":"map","entries":[["correctness",{"type":"ndarray","array":{"type":"bytes","data":"AAAAAAAARkA="},"shape":[1],"dtype":"float64","order":"little"}],["metadata_values",["Others"]],["colors",["#a50026"]]]}}},"view":{"type":"object","name":"CDSView","id":"p1949","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1950"}}},"glyph":{"type":"object","name":"HBar","id":"p1945","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"#1f77b4"},"fill_color":{"type":"value","value":"#14191B"}}},"nonselection_glyph":{"type":"object","name":"HBar","id":"p1946","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"#1f77b4"},"line_alpha":{"type":"value","value":0.1},"fill_color":{"type":"value","value":"#14191B"},"fill_alpha":{"type":"value","value":0.1},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"HBar","id":"p1947","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"#1f77b4"},"line_alpha":{"type":"value","value":0.2},"fill_color":{"type":"value","value":"#14191B"},"fill_alpha":{"type":"value","value":0.2},"hatch_alpha":{"type":"value","value":0.2}}}}},{"type":"object","name":"GlyphRenderer","id":"p1957","attributes":{"data_source":{"id":"p1916"},"view":{"type":"object","name":"CDSView","id":"p1958","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1959"}}},"glyph":{"type":"object","name":"HBar","id":"p1954","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"white"},"line_width":{"type":"value","value":2},"fill_color":{"type":"value","value":"#78BBFA"},"fill_alpha":{"type":"value","value":0.7}}},"nonselection_glyph":{"type":"object","name":"HBar","id":"p1955","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"white"},"line_alpha":{"type":"value","value":0.1},"line_width":{"type":"value","value":2},"fill_color":{"type":"value","value":"#78BBFA"},"fill_alpha":{"type":"value","value":0.1},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"HBar","id":"p1956","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"white"},"line_alpha":{"type":"value","value":0.2},"line_width":{"type":"value","value":2},"fill_color":{"type":"value","value":"#78BBFA"},"fill_alpha":{"type":"value","value":0.2},"hatch_alpha":{"type":"value","value":0.2}}}}},{"type":"object","name":"GlyphRenderer","id":"p1967","attributes":{"visible":false,"data_source":{"type":"object","name":"ColumnDataSource","id":"p1961","attributes":{"selected":{"type":"object","name":"Selection","id":"p1962","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1963"},"data":{"type":"map","entries":[["x",[0]],["y",[0]]]}}},"view":{"type":"object","name":"CDSView","id":"p1968","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1969"}}},"glyph":{"type":"object","name":"Line","id":"p1964","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"line_color":"#EA3829","line_width":2,"line_dash":[6]}},"nonselection_glyph":{"type":"object","name":"Line","id":"p1965","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"line_color":"#EA3829","line_alpha":0.1,"line_width":2,"line_dash":[6]}},"muted_glyph":{"type":"object","name":"Line","id":"p1966","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"line_color":"#EA3829","line_alpha":0.2,"line_width":2,"line_dash":[6]}}}}],"toolbar":{"type":"object","name":"Toolbar","id":"p1927","attributes":{"tools":[{"type":"object","name":"HoverTool","id":"p1941","attributes":{"renderers":"auto","tooltips":[["topic","@metadata_values"],["Correctness","@correctness{0.00}"]]}}]}},"toolbar_location":null,"left":[{"type":"object","name":"CategoricalAxis","id":"p1936","attributes":{"ticker":{"type":"object","name":"CategoricalTicker","id":"p1937"},"formatter":{"type":"object","name":"CategoricalTickFormatter","id":"p1938"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1939"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"below":[{"type":"object","name":"LinearAxis","id":"p1931","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p1932","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p1933"},"axis_label":"Correctness (%)","axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1934"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"center":[{"type":"object","name":"Grid","id":"p1935","attributes":{"axis":{"id":"p1931"},"grid_line_color":"#E0E0E0","grid_line_alpha":0.25}},{"type":"object","name":"Grid","id":"p1940","attributes":{"dimension":1,"axis":{"id":"p1936"},"grid_line_color":"#E0E0E0","grid_line_alpha":0.25}},{"type":"object","name":"Span","id":"p1960","attributes":{"location":44.0,"dimension":"height","line_color":"#EA3829","line_width":2,"line_dash":[6]}},{"type":"object","name":"Legend","id":"p1970","attributes":{"border_line_alpha":0,"background_fill_color":"#111516","background_fill_alpha":0.5,"label_text_color":"#E0E0E0","label_text_font":"Helvetica","label_text_font_size":"1.025em","label_standoff":8,"glyph_width":15,"spacing":8,"items":[{"type":"object","name":"LegendItem","id":"p1971","attributes":{"label":{"type":"value","value":"Correctness on the entire Testset"},"renderers":[{"id":"p1967"}]}}]}}],"background_fill_color":"#14191B","border_fill_color":"#15191C"}}]}}';
        const render_items = [{"docid":"b058a463-6cca-4faf-b68b-943fe9854835","roots":{"p1919":"f4b2f0c3-2e87-4ef2-9230-0389f6a23a79"},"root_ids":["p1919"]}];
        root.Bokeh.embed.embed_items(docs_json, render_items);
        }
        if (root.Bokeh !== undefined) {
          embed_document(root);
        } else {
          let attempts = 0;
          const timer = setInterval(function(root) {
            if (root.Bokeh !== undefined) {
              clearInterval(timer);
              embed_document(root);
            } else {
              attempts++;
              if (attempts > 100) {
                clearInterval(timer);
                console.log("Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing");
              }
            }
          }, 10, root)
        }
      })(window);
    });
  };
  if (document.readyState != "loading") fn();
  else document.addEventListener("DOMContentLoaded", fn);
})();
    </script>

                <div id="f4b2f0c3-2e87-4ef2-9230-0389f6a23a79" data-root-id="p1919" style="display: contents;"></div>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">
                <div class="section-title">KNOWLEDGE BASE OVERVIEW</div>
                    <script type="text/javascript">
        (function() {
  const fn = function() {
    Bokeh.safely(function() {
      (function(root) {
        function embed_document(root) {
        const docs_json = '{"3f75ef7e-eede-4b3b-80b8-9f9fa23c2c27":{"version":"3.4.3","title":"Bokeh Application","roots":[{"type":"object","name":"Tabs","id":"p1850","attributes":{"sizing_mode":"stretch_width","tabs":[{"type":"object","name":"TabPanel","id":"p1780","attributes":{"title":"Topic exploration","child":{"type":"object","name":"Figure","id":"p1733","attributes":{"sizing_mode":"stretch_width","x_range":{"type":"object","name":"Range1d","id":"p1742","attributes":{"start":18.198260021209716,"end":25.702872848510744}},"y_range":{"type":"object","name":"Range1d","id":"p1743","attributes":{"start":1.393630862236023,"end":7.908727288246155}},"x_scale":{"type":"object","name":"LinearScale","id":"p1744"},"y_scale":{"type":"object","name":"LinearScale","id":"p1745"},"title":{"type":"object","name":"Title","id":"p1740","attributes":{"text_color":"#E0E0E0","text_font":"Helvetica","text_font_size":"14pt"}},"outline_line_color":"#E0E0E0","outline_line_alpha":0.25,"renderers":[{"type":"object","name":"GlyphRenderer","id":"p1773","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p1730","attributes":{"selected":{"type":"object","name":"Selection","id":"p1731","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1732"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"eC2aQcdnk0GgzJNBuiKaQST4n0Go+LNBtr6jQXzzr0EBubRBsc6vQeqmq0E1lqhBUV+eQbqhpkE3PaxB/XKjQT5JoEGYyrdBKBupQWCIsEHxpqtByIixQS0GqUEPH6RB"},"shape":[24],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"a0qCQKedf0BZ0UpAxidSQAqaKkDwl6BAg1OKQCZYkECOi79Al7HRQAuEv0BSr9dAOA2qQIK3q0Co6KlAl1DEQARV2kBLWIlA00qQQFttd0DeT1lA5eY4QM6vHkCrsktA"},"shape":[24],"dtype":"float32","order":"little"}],["topic",["Nasal Decongestant","Nasal Decongestant","Nasal Decongestant","Nasal Decongestant","Nasal Decongestant","Prostate Cancer Immunotherapy","Others","Prostate Cancer Immunotherapy","Others","Prostate Cancer Immunotherapy","Prostate Cancer Immunotherapy","Prostate Cancer Immunotherapy","Others","Prostate Cancer Immunotherapy","Prostate Cancer Immunotherapy","Prostate Cancer Immunotherapy","Others","Others","Prostate Cancer Immunotherapy","Prostate Cancer Immunotherapy","Prostate Cancer Immunotherapy","Others","Others","Nasal Decongestant"]],["id",[0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23]],["content",["AFRIN NODRIP ALLERGY SINUS NIGHT- oxymetazoline hydrochloride spray \\n \\nBayer HealthCare LLC.\\n----------\\nAfrin NoDrip Allergy Sinus Night UI1612461\\nDrug Facts\\nActive ingredient \\nPurpose\\nOxymetazoline hydrochloride 0.05%\\u2026\\u2026.\\u2026....Nasal decongestant\\nUses\\n\\u25aa \\ntemporarily relieves nasal congestion due to:\\n\\u25aa \\ncommon cold \\n\\u25aahay fever\\n\\u25aa \\nupper respiratory allergies\\n\\u25aa \\nreduces swelling of nasal passages so you can breathe more freely\\n\\u25aa \\ntemporarily relieves sinus congestion and pressure\\nWarnings\\n\\u25aa \\nAsk a do...","supervision): 2 or 3 sprays in each nostril not more often than\\nevery 10 to 12 hours. Do not exceed 2 doses in any 24-hour\\nperiod.\\n\\u25aa children under 6 years of age: ask a doctor\\nTo Use: Shake well before use. Hold white tabs, press grooved area of cap firmly and\\nturn counter clockwise. Before using the first time, prime metered pump by depressing\\npump firmly several times. To spray, hold bottle with thumb at base and nozzle between\\nfirst and second fingers. Without tilting head, insert nozzle int...","Oxymetazoline HCl\\nNasal Solution-Nasal Decongestant\\nAFRIN\\nNODRIP\\nWont drive from nose or down throat\\nAllergy Sinus\\nNight\\nwith soothing chamomile scent\\nPUMP MIST\\nInstant Congestion","Relief from Allergies\\nfor a More Restful Night\\nReduces\\nSwelling of\\nNasal\\nPassages\\n1/2 FL OZ (15mL)\\nAFRIN NODRIP ALLERGY SINUS NIGHT  \\noxymetazoline hydrochloride spray\\nProduct Information\\nProduct Type\\nHUMAN OTC DRUG\\nItem Code (Source)\\nNDC:11523-0034\\nRoute of Administration\\nNASAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nOXYMETAZOLINE HYDROCHLORIDE\\n (UNII: K89MJ0S5VY) \\n(OXYMETAZOLINE\\n- UNII:8VLN5B44ZY)\\nOXYMETAZOLINE\\nHYDROCHLORIDE\\n0.5 mg\\n in 1 mL\\nInactive Ingredien...","Bayer HealthCare LLC.\\nMarketing Information\\nMarketing\\nCategory\\nApplication Number or Monograph\\nCitation\\nMarketing Start\\nDate\\nMarketing End\\nDate\\nOTC Monograph Drug\\nM012\\n11/09/2020\\nLabeler - \\nBayer HealthCare LLC. \\n(112117283)\\n \\nRevised: 12/2024","PROVENGE- sipuleucel-t injection \\n \\nDendreon Pharmaceuticals LLC\\n----------\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\nThese highlights do not include all the information needed to use PROVENGE \\n (sipuleucel-\\nT) safely and effectively. See full prescribing information for PROVENGE. \\nPROVENGE \\n (sipuleucel-T) \\nSuspension for Intravenous Infusion \\nInitial U.S. Approval: 2010\\nRECENT MAJOR CHANGES\\nDosage and Administration\\n     Administration ( \\n2.2\\n)\\n9/2014\\nWarnings and Precautions\\n     Acute Infusion R...","ADVERSE REACTIONS\\nThe most common adverse reactions (incidence \\u2265 15%) are chills, fatigue, fever, back pain, nausea, joint\\nache, and headache. ( \\n6\\n)\\nTo report SUSPECTED ADVERSE REACTIONS, contact Dendreon Pharmaceuticals LLC at 1-\\n877-336-3736 or FDA at 1-800-FDA-1088 or \\nwww.fda.gov/medwatch\\n.\\nSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.\\nRevised: 7/2017\\nFULL PRESCRIBING INFORMATION: CONTENTS\\n*\\n1 INDICATIONS AND USAGE\\n2 DOSAGE AND ADMINISTRATION\\n2.1 Dose\\n2.2 Admi...","PROVENGE \\n (sipuleucel-T) is an autologous cellular immunotherapy indicated for the\\ntreatment of asymptomatic or minimally symptomatic metastatic castrate-resistant\\n(hormone-refractory) prostate cancer.\\n2 DOSAGE AND ADMINISTRATION\\nFor autologous use only.\\nFor intravenous use only.\\n2.1 Dose\\nEach dose of PROVENGE contains a minimum of 50 million autologous CD54 \\n cells\\nactivated with PAP-GM-CSF [ \\nsee Description ( \\n11\\n) \\n].\\nThe recommended course of therapy for PROVENGE is 3 complete doses, given...","3\\n. \\nMatch the patient&#x27;s identity with the patient identifiers on the Final\\nProduct Disposition Notification form and the PROVENGE infusion bag.\\n4\\n. \\nInfuse the entire volume of the PROVENGE infusion bag intravenously over\\napproximately 60 minutes. \\nDo not use a cell filter.\\n5\\n. \\nObserve the patient for acute infusion reactions for at least 30 minutes following\\neach infusion.\\nIf acute infusion reactions occur, such as chills, fatigue, fever, nausea, and joint\\nache, interrupt or slow the infusion...","ache, nausea, and vomiting. The incidence of severe events was greater following the\\nsecond infusion (2.1% vs. 0.8% following the first infusion), and decreased to 1.3%\\nfollowing the third infusion. Some (1.2%) patients in the PROVENGE group were\\nhospitalized within 1 day of infusion for management of acute infusion reactions. No\\nGrade 4 or 5 acute infusion reactions were reported in patients in the PROVENGE group.\\nIn controlled clinical trials, severe (Grade 3) acute infusion reactions were rep...","Provenge. The clinical significance and causal relationship are uncertain. Most patients\\nhad multiple risk factors for these events. \\nCardiovascular disorders\\n:  In controlled clinical\\ntrials, myocardial infarctions were observed in 0.8% of patients in the PROVENGE group\\ncompared with 0.3% of patients in the control group.  In the postmarketing setting,\\nmyocardial infarctions have been observed following infusion of Provenge. The clinical\\nsignificance and causal relationship are uncertain. Most ...","PROVENGE group who underwent at least 1 leukapheresis procedure in four\\nrandomized, controlled clinical trials. The control group (n = 303) received non-activated\\nautologous peripheral blood mononuclear cells. Patients received 3 infusions of\\nPROVENGE or control every other week over a period of 4 weeks.\\nAlmost all (98.3%) patients in the PROVENGE group and 96% in the control group\\nreported an adverse event. In 67.4% of patients in the PROVENGE group, these adverse\\nevents were mild or moderate i...","Control group received non-activated autologous peripheral blood mononuclear cells.\\nNausea\\n129 (21.5)\\n3 (0.5)\\n45 (14.9)\\n0 (0.0)\\nJoint ache\\n118 (19.6)\\n11 (1.8)\\n62 (20.5)\\n5 (1.7)\\nHeadache\\n109 (18.1)\\n4 (0.7)\\n20 (6.6)\\n0 (0.0)\\nCitrate toxicity\\n89 (14.8)\\n0 (0.0)\\n43 (14.2)\\n0 (0.0)\\nParesthesia\\n85 (14.1)\\n1 (0.2)\\n43 (14.2)\\n0 (0.0)\\nVomiting\\n80 (13.3)\\n2 (0.3)\\n23 (7.6)\\n0 (0.0)\\nAnemia\\n75 (12.5)\\n11 (1.8)\\n34 (11.2)\\n7 (2.3)\\nConstipation\\n74 (12.3)\\n1 (0.2)\\n40 (13.2)\\n3 (1.0)\\nPain\\n74 (12.3)\\n7 (1.2)\\n20 (6.6)\\n3 (1.0)\\n...","The following adverse reactions have been identified during post-approval use of\\nPROVENGE. Because these reactions are reported voluntarily from a population of\\nuncertain size, it is not always possible to reliably estimate their frequency or establish a\\ncausal relationship to drug exposure.\\nNervous system disorders\\n:\\n syncope, transient ischemic attack, strokes [see\\nWarnings and Precautions ( \\n5.1\\n, \\n5.3\\n)]\\nVascular disorders\\n:\\n hypotension [see \\nWarnings and Precautions ( \\n5.1\\n)]\\nCardiovascula...","CSF, consisting of prostatic acid phosphatase (PAP), an antigen expressed in prostate\\ncancer tissue, linked to granulocyte-macrophage colony-stimulating factor (GM-CSF), an\\nimmune cell activator. Each dose of PROVENGE contains a minimum of 50 million\\nautologous CD54 \\n cells activated with PAP-GM-CSF, suspended in 250 mL of Lactated\\nRinger&#x27;s Injection, USP.\\nThe active components of PROVENGE are autologous APCs and PAP-GM-CSF. During\\nculture, the recombinant antigen can bind to and be processed by...","13 NONCLINICAL TOXICOLOGY\\n14 CLINICAL STUDIES\\nThe effect of PROVENGE on patients with metastatic castrate-resistant (hormone-\\nrefractory) prostate cancer was studied in three similar randomized, double-blind,\\nplacebo-controlled, multicenter trials. Following randomization, patients from both\\ntreatment groups underwent a series of 3 leukapheresis procedures (at approximately\\nWeeks 0, 2, and 4). Each leukapheresis was followed approximately 3 days later by\\ninfusion of PROVENGE or control. The cont...","Table 2 Summary of Overall Survival (All Patients as Randomized)\\n Hazard ratio and p-value based on the Cox Model adjusted for PSA (ln) and LDH (ln) and stratified\\nby bisphosphonate use, number of bone metastases, and primary Gleason grade.\\n Hazard ratio based on the unadjusted Cox Model (not pre-specified).\\n p-value based on a log-rank test (not pre-specified).\\nAbbreviations: CI = confidence interval.\\nStudy 1\\nStudy 2\\nPROVENGE \\n(N=341)\\nControl \\n(N=171)\\nPROVENGE\\n(N=82)\\nControl \\n(N=45)\\nOverall Sur...","NDC 30237-8900-6: One bag individually packed in a carton.\\nPROVENGE is shipped directly to the infusing provider in a cardboard shipping box with\\na special insulated polyurethane container inside. The insulated container and gel packs\\nwithin the container are designed to maintain the appropriate transportation and storage\\ntemperature of PROVENGE until infusion.\\nUpon receipt, open the outer cardboard shipping box to verify the product and\\npatient-specific labels located on the top of the insulate...","PROVENGE\\n(sipuleucel-T)\\nThis leaflet is designed to help you understand treatment with PROVENGE (pronounced\\nPROH-venj). The more you understand your treatment, the better you will be able to\\nparticipate in your care. This leaflet does not take the place of talking with your doctor or\\nhealthcare professional about your medical condition or your treatment. If you have any\\nquestions, speak with your doctor.\\nWhat is PROVENGE?\\nPROVENGE is a prescription medicine that is used to treat certain patients...","PROVENGE. Any of these may be signs of heart or lung problems.\\nyou develop numbness or weakness on one side of the body, decreased vision in one\\neye or difficulty speaking. Any of these may be signs of a stroke.\\nyou develop symptoms of thrombosis which may include: pain and/or swelling of an\\narm or leg with warmth over the affected area, discoloration of an arm or leg,\\nunexplained shortness of breath, chest pain that worsens on deep breathing.\\nyou get a fever over 100\\u00baF, or redness or pain at th...","Principal Display Panel \\u2013 Bag Label\\nNDC 30237-8900-5\\nsipuleucel-T\\nPROVENGE \\nRX ONLY FOR AUTOLOGOUS USE ONLY\\nNo U.S. standard of potency\\nCONTENTS: A minimum of 50 million autologous CD54 \\n cells activated with PAP-GM-CSF\\nand suspended in Lactated Ringer&#x27;s Injection, USP.\\nManufactured by:\\nDendreon Pharmaceuticals LLC Seal Beach, CA 90740\\nPhone: 877-256-4545\\nU.S. Lic. # 1749\\nNo preservatives. Gently mix and re-suspend the contents of the bag. 000074.01\\nOne autologous dose for infusion. See package ...","Package Label 2\\nsipuleucel-T 250 mL Lot XXXXXX-X\\nStore Refrigerated 2-8\\u00b0C DO NOT FREEZE\\nExpiration Date: DD-MMM-YYYY\\nExpiration Time: XX:XX Time Zone:\\nFirst Name MI:\\nLast Name:\\nDate of Birth: DD-MMM-YYYY\\nNOT EVALUATED FOR INFECTIOUS SUBSTANCES\\nPROVENGE  \\nsipuleucel-t injection","Product Information\\nProduct Type\\nCELLULAR THERAPY\\nItem Code (Source)\\nNDC:30237-8900\\nRoute of Administration\\nINTRAVENOUS\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nSIPULEUCEL-T\\n (UNII: 8Q622VDR18) \\n(SIPULEUCEL-T - UNII:8Q622VDR18)\\nSIPULEUCEL-T\\n50000000 \\nInactive Ingredients\\nIngredient Name\\nStrength\\nPOTASSIUM CHLORIDE\\n (UNII: 660YQ98I10)\\n \\nCALCIUM CHLORIDE\\n (UNII: M4I0D6VV5M)\\n \\nWATER\\n (UNII: 059QF0KO0R)\\n \\nSODIUM CHLORIDE\\n (UNII: 451W47IQ8X)\\n \\nSODIUM LACTATE\\n (UNII: ...","Dendreon Pharmaceuticals LLC\\nPharmaceuticals LLC\\n968590237\\n, label(30237-8900)\\n \\nRevised: 10/2024"]],["color",{"type":"ndarray","array":["#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#aec7e8","#999","#aec7e8","#999","#aec7e8","#aec7e8","#aec7e8","#999","#aec7e8","#aec7e8","#aec7e8","#999","#999","#aec7e8","#aec7e8","#aec7e8","#999","#999","#1f77b4"],"shape":[24],"dtype":"object","order":"little"}]]}}},"view":{"type":"object","name":"CDSView","id":"p1774","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1775"}}},"glyph":{"type":"object","name":"Scatter","id":"p1770","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.7},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.7}}},"nonselection_glyph":{"type":"object","name":"Scatter","id":"p1771","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.1},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.1},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"Scatter","id":"p1772","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.2},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.2}}}}}],"toolbar":{"type":"object","name":"Toolbar","id":"p1741","attributes":{"logo":"grey","tools":[{"type":"object","name":"HoverTool","id":"p1756","attributes":{"renderers":"auto","tooltips":"\\n    &lt;div style=\\"width:400px;\\"&gt;\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\n    &lt;b&gt;Document Content:&lt;/b&gt; @content\\n    &lt;/div&gt;\\n    "}},{"type":"object","name":"PanTool","id":"p1757"},{"type":"object","name":"WheelZoomTool","id":"p1758","attributes":{"renderers":"auto"}},{"type":"object","name":"BoxZoomTool","id":"p1759","attributes":{"overlay":{"type":"object","name":"BoxAnnotation","id":"p1760","attributes":{"syncable":false,"level":"overlay","visible":false,"left":{"type":"number","value":"nan"},"right":{"type":"number","value":"nan"},"top":{"type":"number","value":"nan"},"bottom":{"type":"number","value":"nan"},"left_units":"canvas","right_units":"canvas","top_units":"canvas","bottom_units":"canvas","line_color":"black","line_alpha":1.0,"line_width":2,"line_dash":[4,4],"fill_color":"lightgrey","fill_alpha":0.5}}}},{"type":"object","name":"ResetTool","id":"p1765"},{"type":"object","name":"SaveTool","id":"p1766"}]}},"left":[{"type":"object","name":"LinearAxis","id":"p1751","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p1752","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p1753"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1754"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"below":[{"type":"object","name":"LinearAxis","id":"p1746","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p1747","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p1748"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1749"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"center":[{"type":"object","name":"Grid","id":"p1750","attributes":{"axis":{"id":"p1746"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Grid","id":"p1755","attributes":{"dimension":1,"axis":{"id":"p1751"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Legend","id":"p1776","attributes":{"title":"Knowledge Base Tospics","title_text_color":"#B1B1B1","title_text_font_style":"bold","border_line_alpha":0,"background_fill_color":"#111516","background_fill_alpha":0.5,"label_text_color":"#E0E0E0","label_text_font":"Helvetica","label_text_font_size":"1.025em","label_standoff":8,"glyph_width":15,"spacing":8,"items":[{"type":"object","name":"LegendItem","id":"p1777","attributes":{"label":{"type":"value","value":"Nasal Decongestant"},"renderers":[{"id":"p1773"}],"index":0}},{"type":"object","name":"LegendItem","id":"p1778","attributes":{"label":{"type":"value","value":"Others"},"renderers":[{"id":"p1773"}],"index":6}},{"type":"object","name":"LegendItem","id":"p1779","attributes":{"label":{"type":"value","value":"Prostate Cancer Immunotherapy"},"renderers":[{"id":"p1773"}],"index":5}}]}}],"background_fill_color":"#14191B","border_fill_color":"#15191C"}}}},{"type":"object","name":"TabPanel","id":"p1849","attributes":{"title":"Failures","child":{"type":"object","name":"Figure","id":"p1785","attributes":{"sizing_mode":"stretch_width","x_range":{"type":"object","name":"Range1d","id":"p1794","attributes":{"start":18.198260021209716,"end":25.702872848510744}},"y_range":{"type":"object","name":"Range1d","id":"p1795","attributes":{"start":1.393630862236023,"end":7.908727288246155}},"x_scale":{"type":"object","name":"LinearScale","id":"p1796"},"y_scale":{"type":"object","name":"LinearScale","id":"p1797"},"title":{"type":"object","name":"Title","id":"p1792","attributes":{"text_color":"#E0E0E0","text_font":"Helvetica","text_font_size":"14pt"}},"outline_line_color":"#E0E0E0","outline_line_alpha":0.25,"renderers":[{"type":"object","name":"GlyphRenderer","id":"p1824","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p1781","attributes":{"selected":{"type":"object","name":"Selection","id":"p1782","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1783"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"yIixQQ8fpEE+SaBBNZaoQf1yo0HxpqtBx2eTQZjKt0Gxzq9BKBupQXzzr0Ek+J9B6qarQTc9rEGgzJNBLQapQbqhpkF4LZpBAbm0QWCIsEG2vqNBqPizQVFfnkG6IppBNz2sQQ=="},"shape":[25],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"5eY4QKuyS0AEVdpAUq/XQJdQxEDeT1lAp51/QEtYiUCXsdFA00qQQCZYkEAKmipAC4S/QKjoqUBZ0UpAzq8eQIK3q0BrSoJAjou/QFttd0CDU4pA8JegQDgNqkDGJ1JAqOipQA=="},"shape":[25],"dtype":"float32","order":"little"}],["topic",["Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others"]],["correctness",[true,false,false,false,false,false,false,false,true,true,true,false,true,true,false,false,true,true,false,true,false,false,false,true,true]],["questions",["According to the package label information for sipuleucel-T, what are the specific storage conditions, including temperature range, that must be adhered to, and are there any explicit instructions regarding freezing?","Could you specify the unique label number linked to Dendreon Pharmaceuticals LLC, ensuring it is accurate and up-to-date as per the latest revision in October 2024?","In Study 1, what is the median overall survival time in months for patients who received PROVENGE, considering the confidence interval provided?","Considering the PROVENGE group in the clinical trials, what is the percentage of patients who experienced chills as an adverse event, and how does this compare to the control group, especially in terms of severity levels?","In Study 2 of the PROVENGE clinical trials, what was the main endpoint, considering that the analysis of this endpoint did not achieve statistical significance, and how does this relate to the overall survival analysis?","Under the condition that there is no U.S. standard of potency, what is the minimum number of autologous CD54 cells activated with PAP-GM-CSF present in a single dose of PROVENGE?","Considering the nasal spray&#x27;s guidelines, how many sprays should an adult administer in each nostril within a 24-hour period, and what is the maximum frequency allowed between doses?","In the scenario where a patient is unable to receive their scheduled infusion of PROVENGE, what specific steps must they take to continue treatment, considering the timing and preparation requirements outlined in the context?","In the context of controlled clinical trials, what is the specific percentage of patients in the PROVENGE group who experienced severe (Grade 3) acute infusion reactions, and how does this compare to the incidence of other grades of infusion reactions reported in the same group?","Could you describe the detailed procedure for receiving PROVENGE treatment, including any necessary preparations and the specific timing and location requirements for cell collection and infusion, while considering any potential complications that might arise?","What specific premedications are advised to be administered to a patient before they receive PROVENGE, and are there any particular timing or dosage instructions for these medications that must be followed?","Considering the marketing information provided for Bayer HealthCare LLC&#x27;s OTC Monograph Drug, what is the exact date when the marketing activities officially commenced, and ensure your answer is based on the specific application number or monograph citation associated with it?","Considering that Provenge is not tested for transmissible infectious diseases, what specific universal precautions should healthcare professionals implement while handling leukapheresis material or Provenge to prevent the transmission of infectious diseases?","Considering the cellular composition of PROVENGE and the role of CD54, how does the increased expression of CD54 on APCs after culture with PAP-GM-CSF contribute to the treatment&#x27;s potency, and what implications might this have for its effectiveness in prostate cancer therapy?","Identify the active compound present in the nasal decongestant product mentioned in the context, ensuring to specify if it has any unique properties or formulation details.","Considering the cellular therapy product with the item code NDC:30237-8900, can you specify the method of administration, ensuring you also mention any specific conditions or limitations related to its intravenous use?","Could you detail some adverse reactions linked to the use of PROVENGE that have been observed after its approval, and specify if these include any disorders related to the nervous or cardiovascular systems?","Could you specify the active ingredient found in Afrin NoDrip Allergy Sinus Night, including its concentration, and explain its intended medical purpose, considering any potential restrictions for individuals with specific health conditions?","If a patient experiences acute infusion reactions like chills, fatigue, or fever during the PROVENGE infusion, what specific steps should be taken, considering the infusion bag must not exceed room temperature for more than 3 hours?","Considering the information provided, can you detail the active components found in PROVENGE, including any specific proteins or cells involved, and any conditions related to their use?","Considering the adverse reactions with an incidence rate of 15% or higher, can you specify which ones are frequently reported for this drug, and provide details on how to report any suspected adverse reactions?","Considering the administration guidelines for PROVENGE, what is the recommended schedule for its administration, including any premedication requirements and conditions under which additional leukapheresis might be necessary?","Considering the data provided for the control group, what is the precise percentage of patients who experienced nausea, and how does this compare to other common side effects listed in the same group?","Considering the composition of Afrin NoDrip Allergy Sinus Night spray, can you identify the primary active ingredient responsible for its efficacy, and ensure that your response excludes any inactive ingredients?","Considering the role of CD54, also referred to as ICAM-1, in immune interactions, how does its increased expression on APCs after being cultured with PAP-GM-CSF contribute to the effectiveness of PROVENGE, and what implications might this have on the treatment&#x27;s ability to target prostate cancer antigens?"]],["agent_answer",["According to the package label information for sipuleucel-T, the specific storage conditions require refrigeration at 2\\u00b0C to 8\\u00b0C (36\\u00b0F to 46\\u00b0F). There are explicit instructions stating that sipuleucel-T should not be frozen.","As an AI language model, I do not have real-time information or the ability to access databases to provide specific label numbers for companies. It is recommended to refer to official sources such as the company&#x27;s website, the US Food and Drug Administration (FDA), or other regulatory agencies for the most up-to-date and accurate information regarding Dendreon Pharmaceuticals LLC&#x27;s unique label number as of October 2024.","In Study 1, the median overall survival time in months for patients who received PROVENGE is 25.8 months, with a 95% confidence interval of 23.0 to 28.3 months.","In the PROVENGE group, 10.8% of patients experienced chills as an adverse event. This percentage is higher compared to the control group, where only 1.5% of patients experienced chills. Additionally, the severity levels of chills were also higher in the PROVENGE group, with more patients reporting moderate to severe chills compared to the control group.","In Study 2 of the PROVENGE clinical trials, the main endpoint was overall survival. The analysis of this endpoint did not achieve statistical significance, meaning that the treatment group did not show a significant improvement in overall survival compared to the control group.\\n\\nThis lack of statistical significance in the overall survival analysis suggests that the treatment did not have a significant impact on prolonging patients&#x27; lives. This is important because overall survival is a key measure of the effectiveness of a treatment in cancer clinical trials. If a treatment does not show a significant improvement in overall survival, it may not be considered as effective as initially hoped.\\n\\nOverall, the lack of statistical significance in the overall survival analysis in Study 2 of the PROVENGE clinical trials indicates that the treatment did not meet the primary endpoint of the trial and may not provide a meaningful benefit to patients in terms of extending their lives.","The minimum number of autologous CD54 cells activated with PAP-GM-CSF present in a single dose of PROVENGE is 10^7 cells.","According to the nasal spray&#x27;s guidelines, an adult should administer 1 to 2 sprays in each nostril every 12 hours, not exceeding a total of 2 sprays in each nostril within a 24-hour period. The maximum frequency allowed between doses is every 12 hours.","If a patient is unable to receive their scheduled infusion of PROVENGE, they should contact their healthcare provider immediately to discuss the situation. The healthcare provider will likely reschedule the infusion as soon as possible to ensure the continued treatment.\\n\\nIt is important for the patient to follow any specific instructions provided by their healthcare provider regarding preparation requirements for the next infusion. This may include fasting or other dietary restrictions, as well as any necessary blood work or other tests that need to be completed before the infusion.\\n\\nTiming is crucial in the treatment with PROVENGE, so it is important for the patient to be proactive in communicating with their healthcare provider and scheduling the rescheduled infusion as soon as possible to minimize any potential delays in treatment.","In the context of controlled clinical trials, the specific percentage of patients in the PROVENGE group who experienced severe (Grade 3) acute infusion reactions was 3.5%. This incidence of Grade 3 infusion reactions was lower compared to the overall incidence of infusion reactions in the same group, which was 19.1%.","PROVENGE is a personalized cellular immunotherapy treatment approved by the FDA for patients with advanced prostate cancer. The procedure for receiving PROVENGE involves several steps, including cell collection, preparation, and infusion. \\n\\n1. Consultation and Evaluation: Before starting PROVENGE treatment, the patient will need to undergo a consultation with their oncologist to determine if they are a suitable candidate for the therapy. This may involve a physical exam, blood tests, and imaging studies to assess disease progression.\\n\\n2. Cell Collection: The first step in receiving PROVENGE treatment involves collecting a sample of the patient&#x27;s own immune cells called dendritic cells. This is done through a process called leukapheresis, where blood is taken from the patient through a vein, separated in a machine to collect the dendritic cells, and then returned to the patient. This process typically takes a few hours and may be done at a specialized treatment center or hospital.\\n\\n3. Cell Preparation: The collected dendritic cells are sent to a lab where they are processed and activated with a fusion protein called PAP-GM-CSF, which helps stimulate the immune response against prostate cancer cells. This process takes approximately 2-3 days.\\n\\n4. Infusion: Once the dendritic cells are prepared, they are infused back into the patient through a vein in a procedure known as leukapheresis. This infusion typically takes about 60 minutes and can be done in an outpatient setting.\\n\\n5. Timing and Location: The timing of the cell collection and infusion procedures will be coordinated by the healthcare team based on the patient&#x27;s schedule and the lab processing time. These procedures may need to be scheduled a few days apart to allow for cell processing. The infusion can typically be done at a treatment center or hospital that is equipped to handle cellular immunotherapy.\\n\\n6. Potential Complications: While PROVENGE is generally well-tolerated, there are potential complications that can arise from the treatment. These may include infusion reactions, flu-like symptoms, fever, chills, fatigue, and back pain. In rare cases, more serious side effects such as infection or allergic reactions may occur. Patients should be monitored closely during and after the infusion for any signs of complications.\\n\\nIn conclusion, the procedure for receiving PROVENGE treatment involves cell collection, preparation, and infusion, which are coordinated by the healthcare team to ensure the best possible outcomes for the patient. Patients should be informed about the potential complications associated with the treatment and monitored closely throughout the process.","Before receiving PROVENGE, patients are advised to be administered acetaminophen and an antihistamine such as diphenhydramine. These medications should be given 30 minutes prior to the infusion of PROVENGE. The recommended dosage for acetaminophen is 650 mg orally, and for diphenhydramine, it is 25-50 mg orally or intravenously. It is important to follow these specific timing and dosage instructions to help prevent potential infusion reactions.","Based on the marketing information provided for Bayer HealthCare LLC&#x27;s OTC Monograph Drug, the marketing activities officially commenced on June 28, 2010. This information is based on the specific application number or monograph citation associated with the OTC Monograph Drug.","Healthcare professionals should wear appropriate personal protective equipment (such as gloves, masks, and gowns) while handling leukapheresis material or Provenge. They should also follow standard protocols for handling and disposing of biohazardous materials, including proper hand hygiene practices. In addition, healthcare professionals should follow guidelines for preventing the transmission of bloodborne pathogens, such as HIV and hepatitis, by using safety devices for needle sticks and practicing safe injection practices. Regular training and education on infection control measures should also be provided to healthcare professionals to ensure adherence to universal precautions.","The increased expression of CD54 on APCs after culture with PAP-GM-CSF contributes to the treatment&#x27;s potency by enhancing the ability of APCs to interact with T cells. CD54, also known as ICAM-1, is a cell adhesion molecule that plays a crucial role in facilitating T cell activation and proliferation. By upregulating CD54 expression, APCs are better able to form stable interactions with T cells, leading to more effective antigen presentation and T cell priming.\\n\\nIn the context of PROVENGE therapy for prostate cancer, this increased expression of CD54 on APCs can have significant implications for treatment effectiveness. By enhancing the interaction between APCs and T cells, the therapy may lead to improved T cell activation and proliferation, ultimately enhancing the anti-tumor immune response. This can result in improved tumor targeting and clearance, potentially leading to better outcomes for prostate cancer patients receiving PROVENGE treatment. Overall, the increased expression of CD54 on APCs after culture with PAP-GM-CSF may contribute to the therapy&#x27;s efficacy by enhancing immune cell communication and coordination in the fight against prostate cancer.","The active compound present in the nasal decongestant product mentioned in the context is pseudoephedrine. Pseudoephedrine is a drug that acts as a nasal decongestant and works by constricting blood vessels in the nasal passages, helping to relieve congestion. It is commonly found in many over-the-counter decongestant products. It is important to note that pseudoephedrine is a regulated substance due to its potential use in the illicit production of methamphetamine, so it may require identification and a signature at the time of purchase.","The cellular therapy product with the item code NDC:30237-8900 is typically administered intravenously. However, it is essential to note that the specific method of administration, as well as any specific conditions or limitations related to intravenous use, would be determined by the healthcare provider based on the patient&#x27;s individual needs and medical condition. \\n\\nSome potential limitations related to intravenous administration of cellular therapy products may include:\\n\\n1. Patient&#x27;s vascular access: Ensuring that the patient has proper and adequate vascular access for intravenous administration without any complications such as thrombosis, phlebitis, or leakage.\\n\\n2. Compatibility with intravenous fluids: The cellular therapy product should be compatible with the intravenous fluids that are being used for administration to prevent any interaction or adverse reactions.\\n\\n3. Potential risk of infusion reactions: Some cellular therapy products may have the potential to cause infusion-related reactions, such as fevers, chills, or allergic reactions. Monitoring the patient closely during administration can help identify and manage any adverse reactions promptly.\\n\\nOverall, the method of administration, as well as any specific conditions or limitations related to intravenous use of the cellular therapy product with item code NDC:30237-8900, should be discussed and determined by the healthcare provider in consultation with the patient&#x27;s medical team.","Some adverse reactions linked to the use of PROVENGE that have been observed after its approval include infusion reactions, fatigue, fever, nausea, chills, and back pain. Additionally, some patients may experience serious adverse events such as strokes, heart attacks, pulmonary embolism, allergic reactions, and acute respiratory distress syndrome.\\n\\nThere have been reports of neurological adverse events such as confusion, seizures, and encephalitis in patients receiving PROVENGE. Cardiovascular adverse events such as peripheral edema, arrhythmias, and chest pain have also been reported.\\n\\nIt is important for patients receiving PROVENGE to be closely monitored for any signs or symptoms of adverse reactions, and to report any concerns to their healthcare provider immediately.","The active ingredient found in Afrin NoDrip Allergy Sinus Night is oxymetazoline hydrochloride, with a concentration of 0.05%. Oxymetazoline is a nasal decongestant that works by constricting blood vessels in the nasal passages, leading to reduced swelling and congestion. This helps to relieve symptoms such as stuffy nose and sinus pressure.\\n\\nIt is important to note that oxymetazoline should not be used by individuals with certain health conditions, such as high blood pressure, heart disease, thyroid disorders, diabetes, or prostate problems. Additionally, it should not be used for more than 3 consecutive days, as prolonged use can lead to rebound congestion, where symptoms worsen once the medication is stopped.\\n\\nAs always, it is important to consult with a healthcare provider before using any medication, especially if you have underlying health conditions or concerns about potential side effects.","If a patient experiences acute infusion reactions during the PROVENGE infusion, such as chills, fatigue, or fever, the healthcare provider should stop the infusion immediately and closely monitor the patient. If the symptoms are severe or life-threatening, appropriate medical intervention should be initiated.\\n\\nAt the same time, it is important to ensure that the infusion bag does not exceed room temperature for more than 3 hours. To address this, the healthcare provider should place the infusion bag in a temperature-controlled environment, such as a refrigerator or cooler, while attending to the patient. If necessary, a new infusion bag can be prepared and used once the patient&#x27;s symptoms have been addressed and it is safe to resume the infusion.\\n\\nOverall, the safety and well-being of the patient should be the top priority, and appropriate steps should be taken to address both the acute infusion reactions and the temperature control of the infusion bag.","PROVENGE is a personalized cancer immunotherapy treatment used for the treatment of advanced prostate cancer. The active components found in PROVENGE include autologous antigen presenting cells (APCs) that have been activated with PAP-GM-CSF, a fusion protein that includes prostatic acid phosphatase (PAP) and granulocyte-macrophage colony-stimulating factor (GM-CSF).\\n\\nThe process involves extracting a patient&#x27;s own immune cells, specifically dendritic cells, from their blood. These dendritic cells are then treated with the PAP-GM-CSF fusion protein in a laboratory to stimulate them and enhance their ability to recognize and attack prostate cancer cells.\\n\\nOnce activated, these modified dendritic cells are infused back into the patient, where they stimulate an immune response against the cancer cells expressing the PAP antigen. This immune response aims to target and destroy prostate cancer cells, potentially slowing down the progression of the disease.\\n\\nConditions related to the use of PROVENGE include the requirement for patients to have prior treatment with hormone therapy for prostate cancer that has metastasized and no evidence of disease progression after chemotherapy. Additionally, patients must have sufficient immune cell counts to undergo leukapheresis (a procedure to collect immune cells) and be able to tolerate leukapheresis and infusion procedures.","For a drug with adverse reactions with an incidence rate of 15% or higher, commonly reported side effects may include nausea, headache, dizziness, fatigue, and gastrointestinal disturbances. \\n\\nTo report any suspected adverse reactions, patients and healthcare professionals can notify the FDA through their MedWatch program online at www.fda.gov/medwatch/report.htm or by calling 1-800-FDA-1088. Additionally, adverse reactions can also be reported to the manufacturer of the drug through their contact information provided on the medication packaging or informational leaflet. It is important to report any suspected adverse reactions promptly to ensure patient safety and contribute to the monitoring of drug safety.","PROVENGE should be administered as a single intravenous infusion over approximately 60 minutes. The recommended schedule for administration is three doses at approximately two-week intervals.\\n\\nPremedication with acetaminophen and an antihistamine is recommended prior to each dose of PROVENGE to minimize infusion reactions.\\n\\nAdditional leukapheresis may be necessary if the patient&#x27;s CD54+ cell count is below the required threshold or if the patient&#x27;s leukapheresis product does not meet certain quality control criteria. If additional leukapheresis is needed, it should be performed at least one month after the previous leukapheresis.","Based on the data provided for the control group, the precise percentage of patients who experienced nausea is 10%. This percentage is lower than the percentages for other common side effects listed in the same group, such as headache (15%), dizziness (12%), and fatigue (11%). Nausea is not as common as these other side effects in the control group.","The primary active ingredient in Afrin NoDrip Allergy Sinus Night spray is Oxymetazoline hydrochloride.","CD54, or ICAM-1, plays a crucial role in immune interactions by facilitating the adhesion and recruitment of T cells to antigen-presenting cells (APCs). When APCs are cultured with PAP-GM-CSF, which is a key component of PROVENGE, there is an increase in the expression of CD54 on the APCs. This increased expression of CD54 enhances the interaction between APCs and T cells, leading to improved activation and priming of T cells against prostate cancer antigens presented by the APCs.\\n\\nThis improved T cell activation and priming ultimately contributes to the effectiveness of PROVENGE in targeting prostate cancer antigens. By enhancing the ability of APCs to present prostate cancer antigens to T cells, the increased expression of CD54 on APCs leads to a stronger and more targeted immune response against prostate cancer cells. This can result in a more robust anti-tumor immune response and improved clinical outcomes for patients receiving PROVENGE.\\n\\nIn terms of implications, the enhanced expression of CD54 on APCs cultured with PAP-GM-CSF may improve the specificity and efficacy of PROVENGE in targeting prostate cancer antigens. This could potentially lead to better control of prostate cancer progression and improved survival outcomes for patients. Additionally, the ability of PROVENGE to specifically target prostate cancer antigens may minimize off-target effects and reduce the risk of systemic toxicity compared to more traditional systemic treatments for prostate cancer."]],["reference_answer",["Store Refrigerated 2-8\\u00b0C DO NOT FREEZE","The label number associated with Dendreon Pharmaceuticals LLC is 30237-8900.","The median overall survival for patients treated with PROVENGE in Study 1 is 25.8 months (95% CI: 22.8, 27.7).","53.1% of patients in the PROVENGE group reported chills as an adverse event.","The primary endpoint was time to disease progression; analysis of the primary endpoint did not reach statistical significance.","A minimum of 50 million autologous CD54 cells activated with PAP-GM-CSF.","2 or 3 sprays in each nostril not more often than every 10 to 12 hours. Do not exceed 2 doses in any 24-hour period.","If the patient is unable to receive an infusion of PROVENGE, the patient will need to undergo an additional leukapheresis procedure if the treatment is to be continued.","In controlled clinical trials, severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the PROVENGE group.","Since PROVENGE is made from your own immune cells, your cells will be collected approximately 3 days before each scheduled infusion of PROVENGE. You will need to go to a cell collection center for this collection, called &#x27;leukapheresis.&#x27; Your collected cells are sent to a manufacturing center where they are mixed with a protein to make them ready for your infusion. You will get PROVENGE in 3 intravenous infusions, about 2 weeks apart. Each infusion takes about 60 minutes, and you will be monitored for at least 30 minutes following each infusion.","Premedicate patients with oral acetaminophen and an antihistamine such as diphenhydramine approximately 30 minutes prior to administration of PROVENGE.","The marketing start date is 11/09/2020.","Healthcare professionals should employ universal precautions when handling leukapheresis material or PROVENGE, as it is not tested for transmissible infectious diseases and may carry the risk of transmitting infectious diseases.","The potency of PROVENGE is in part determined by measuring the increased expression of the CD54 molecule, also known as ICAM-1, on the surface of APCs after culture with PAP-GM-CSF. CD54 is a cell surface molecule that plays a role in the immunologic interactions between APCs and T cells, and is considered a marker of immune cell activation.","Oxymetazoline HCl","INTRAVENOUS","The adverse reactions identified include syncope, transient ischemic attack, strokes, hypotension, myocardial infarction, deep venous thrombosis, and pulmonary embolism.","The active ingredient is Oxymetazoline hydrochloride 0.05%, and its purpose is to act as a nasal decongestant.","If acute infusion reactions occur, such as chills, fatigue, fever, nausea, and joint ache, interrupt or slow the infusion and administer appropriate medical treatment as needed. In controlled clinical trials, symptoms of acute infusion reactions were treated with acetaminophen, intravenous H1 and/or H2 blockers, and low-dose intravenous meperidine.","The active components of PROVENGE are your own immune cells mixed with the other active component, a protein designed to produce an immune response to prostate cancer.","The most common adverse reactions (incidence \\u2265 15%) are chills, fatigue, fever, back pain, nausea, joint ache, and headache.","The recommended course of therapy for PROVENGE is 3 complete doses, given at approximately 2-week intervals.","21.5%","The active ingredient is Oxymetazoline Hydrochloride.","The potency of PROVENGE is in part determined by measuring the increased expression of the CD54 molecule, also known as ICAM-1, on the surface of APCs after culture with PAP-GM-CSF. CD54 is a cell surface molecule that plays a role in the immunologic interactions between APCs and T cells, and is considered a marker of immune cell activation."]],["id",[21,23,16,11,15,20,1,17,9,18,7,4,10,14,2,22,13,0,8,19,6,5,12,3,14]],["content",["Package Label 2\\nsipuleucel-T 250 mL Lot XXXXXX-X\\nStore Refrigerated 2-8\\u00b0C DO NOT FREEZE\\nExpiration Date: DD-MMM-YYYY\\nExpiration Time: XX:XX Time Zone:\\nFirst Name MI:\\nLast Name:\\nDate of Birth: DD-MMM-YYYY\\nNOT EVALUATED FOR INFECTIOUS SUBSTANCES\\nPROVENGE  \\nsipuleucel-t injection","Dendreon Pharmaceuticals LLC\\nPharmaceuticals LLC\\n968590237\\n, label(30237-8900)\\n \\nRevised: 10/2024","Table 2 Summary of Overall Survival (All Patients as Randomized)\\n Hazard ratio and p-value based on the Cox Model adjusted for PSA (ln) and LDH (ln) and stratified\\nby bisphosphonate use, number of bone metastases, and primary Gleason grade.\\n Hazard ratio based on the unadjusted Cox Model (not pre-specified).\\n p-value based on a log-rank test (not pre-specified).\\nAbbreviations: CI = confidence interval.\\nStudy 1\\nStudy 2\\nPROVENGE \\n(N=341)\\nControl \\n(N=171)\\nPROVENGE\\n(N=82)\\nControl \\n(N=45)\\nOverall Sur...","PROVENGE group who underwent at least 1 leukapheresis procedure in four\\nrandomized, controlled clinical trials. The control group (n = 303) received non-activated\\nautologous peripheral blood mononuclear cells. Patients received 3 infusions of\\nPROVENGE or control every other week over a period of 4 weeks.\\nAlmost all (98.3%) patients in the PROVENGE group and 96% in the control group\\nreported an adverse event. In 67.4% of patients in the PROVENGE group, these adverse\\nevents were mild or moderate i...","13 NONCLINICAL TOXICOLOGY\\n14 CLINICAL STUDIES\\nThe effect of PROVENGE on patients with metastatic castrate-resistant (hormone-\\nrefractory) prostate cancer was studied in three similar randomized, double-blind,\\nplacebo-controlled, multicenter trials. Following randomization, patients from both\\ntreatment groups underwent a series of 3 leukapheresis procedures (at approximately\\nWeeks 0, 2, and 4). Each leukapheresis was followed approximately 3 days later by\\ninfusion of PROVENGE or control. The cont...","Principal Display Panel \\u2013 Bag Label\\nNDC 30237-8900-5\\nsipuleucel-T\\nPROVENGE \\nRX ONLY FOR AUTOLOGOUS USE ONLY\\nNo U.S. standard of potency\\nCONTENTS: A minimum of 50 million autologous CD54 \\n cells activated with PAP-GM-CSF\\nand suspended in Lactated Ringer&#x27;s Injection, USP.\\nManufactured by:\\nDendreon Pharmaceuticals LLC Seal Beach, CA 90740\\nPhone: 877-256-4545\\nU.S. Lic. # 1749\\nNo preservatives. Gently mix and re-suspend the contents of the bag. 000074.01\\nOne autologous dose for infusion. See package ...","supervision): 2 or 3 sprays in each nostril not more often than\\nevery 10 to 12 hours. Do not exceed 2 doses in any 24-hour\\nperiod.\\n\\u25aa children under 6 years of age: ask a doctor\\nTo Use: Shake well before use. Hold white tabs, press grooved area of cap firmly and\\nturn counter clockwise. Before using the first time, prime metered pump by depressing\\npump firmly several times. To spray, hold bottle with thumb at base and nozzle between\\nfirst and second fingers. Without tilting head, insert nozzle int...","NDC 30237-8900-6: One bag individually packed in a carton.\\nPROVENGE is shipped directly to the infusing provider in a cardboard shipping box with\\na special insulated polyurethane container inside. The insulated container and gel packs\\nwithin the container are designed to maintain the appropriate transportation and storage\\ntemperature of PROVENGE until infusion.\\nUpon receipt, open the outer cardboard shipping box to verify the product and\\npatient-specific labels located on the top of the insulate...","ache, nausea, and vomiting. The incidence of severe events was greater following the\\nsecond infusion (2.1% vs. 0.8% following the first infusion), and decreased to 1.3%\\nfollowing the third infusion. Some (1.2%) patients in the PROVENGE group were\\nhospitalized within 1 day of infusion for management of acute infusion reactions. No\\nGrade 4 or 5 acute infusion reactions were reported in patients in the PROVENGE group.\\nIn controlled clinical trials, severe (Grade 3) acute infusion reactions were rep...","PROVENGE\\n(sipuleucel-T)\\nThis leaflet is designed to help you understand treatment with PROVENGE (pronounced\\nPROH-venj). The more you understand your treatment, the better you will be able to\\nparticipate in your care. This leaflet does not take the place of talking with your doctor or\\nhealthcare professional about your medical condition or your treatment. If you have any\\nquestions, speak with your doctor.\\nWhat is PROVENGE?\\nPROVENGE is a prescription medicine that is used to treat certain patients...","PROVENGE \\n (sipuleucel-T) is an autologous cellular immunotherapy indicated for the\\ntreatment of asymptomatic or minimally symptomatic metastatic castrate-resistant\\n(hormone-refractory) prostate cancer.\\n2 DOSAGE AND ADMINISTRATION\\nFor autologous use only.\\nFor intravenous use only.\\n2.1 Dose\\nEach dose of PROVENGE contains a minimum of 50 million autologous CD54 \\n cells\\nactivated with PAP-GM-CSF [ \\nsee Description ( \\n11\\n) \\n].\\nThe recommended course of therapy for PROVENGE is 3 complete doses, given...","Bayer HealthCare LLC.\\nMarketing Information\\nMarketing\\nCategory\\nApplication Number or Monograph\\nCitation\\nMarketing Start\\nDate\\nMarketing End\\nDate\\nOTC Monograph Drug\\nM012\\n11/09/2020\\nLabeler - \\nBayer HealthCare LLC. \\n(112117283)\\n \\nRevised: 12/2024","Provenge. The clinical significance and causal relationship are uncertain. Most patients\\nhad multiple risk factors for these events. \\nCardiovascular disorders\\n:  In controlled clinical\\ntrials, myocardial infarctions were observed in 0.8% of patients in the PROVENGE group\\ncompared with 0.3% of patients in the control group.  In the postmarketing setting,\\nmyocardial infarctions have been observed following infusion of Provenge. The clinical\\nsignificance and causal relationship are uncertain. Most ...","CSF, consisting of prostatic acid phosphatase (PAP), an antigen expressed in prostate\\ncancer tissue, linked to granulocyte-macrophage colony-stimulating factor (GM-CSF), an\\nimmune cell activator. Each dose of PROVENGE contains a minimum of 50 million\\nautologous CD54 \\n cells activated with PAP-GM-CSF, suspended in 250 mL of Lactated\\nRinger&#x27;s Injection, USP.\\nThe active components of PROVENGE are autologous APCs and PAP-GM-CSF. During\\nculture, the recombinant antigen can bind to and be processed by...","Oxymetazoline HCl\\nNasal Solution-Nasal Decongestant\\nAFRIN\\nNODRIP\\nWont drive from nose or down throat\\nAllergy Sinus\\nNight\\nwith soothing chamomile scent\\nPUMP MIST\\nInstant Congestion","Product Information\\nProduct Type\\nCELLULAR THERAPY\\nItem Code (Source)\\nNDC:30237-8900\\nRoute of Administration\\nINTRAVENOUS\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nSIPULEUCEL-T\\n (UNII: 8Q622VDR18) \\n(SIPULEUCEL-T - UNII:8Q622VDR18)\\nSIPULEUCEL-T\\n50000000 \\nInactive Ingredients\\nIngredient Name\\nStrength\\nPOTASSIUM CHLORIDE\\n (UNII: 660YQ98I10)\\n \\nCALCIUM CHLORIDE\\n (UNII: M4I0D6VV5M)\\n \\nWATER\\n (UNII: 059QF0KO0R)\\n \\nSODIUM CHLORIDE\\n (UNII: 451W47IQ8X)\\n \\nSODIUM LACTATE\\n (UNII: ...","The following adverse reactions have been identified during post-approval use of\\nPROVENGE. Because these reactions are reported voluntarily from a population of\\nuncertain size, it is not always possible to reliably estimate their frequency or establish a\\ncausal relationship to drug exposure.\\nNervous system disorders\\n:\\n syncope, transient ischemic attack, strokes [see\\nWarnings and Precautions ( \\n5.1\\n, \\n5.3\\n)]\\nVascular disorders\\n:\\n hypotension [see \\nWarnings and Precautions ( \\n5.1\\n)]\\nCardiovascula...","AFRIN NODRIP ALLERGY SINUS NIGHT- oxymetazoline hydrochloride spray \\n \\nBayer HealthCare LLC.\\n----------\\nAfrin NoDrip Allergy Sinus Night UI1612461\\nDrug Facts\\nActive ingredient \\nPurpose\\nOxymetazoline hydrochloride 0.05%\\u2026\\u2026.\\u2026....Nasal decongestant\\nUses\\n\\u25aa \\ntemporarily relieves nasal congestion due to:\\n\\u25aa \\ncommon cold \\n\\u25aahay fever\\n\\u25aa \\nupper respiratory allergies\\n\\u25aa \\nreduces swelling of nasal passages so you can breathe more freely\\n\\u25aa \\ntemporarily relieves sinus congestion and pressure\\nWarnings\\n\\u25aa \\nAsk a do...","3\\n. \\nMatch the patient&#x27;s identity with the patient identifiers on the Final\\nProduct Disposition Notification form and the PROVENGE infusion bag.\\n4\\n. \\nInfuse the entire volume of the PROVENGE infusion bag intravenously over\\napproximately 60 minutes. \\nDo not use a cell filter.\\n5\\n. \\nObserve the patient for acute infusion reactions for at least 30 minutes following\\neach infusion.\\nIf acute infusion reactions occur, such as chills, fatigue, fever, nausea, and joint\\nache, interrupt or slow the infusion...","PROVENGE. Any of these may be signs of heart or lung problems.\\nyou develop numbness or weakness on one side of the body, decreased vision in one\\neye or difficulty speaking. Any of these may be signs of a stroke.\\nyou develop symptoms of thrombosis which may include: pain and/or swelling of an\\narm or leg with warmth over the affected area, discoloration of an arm or leg,\\nunexplained shortness of breath, chest pain that worsens on deep breathing.\\nyou get a fever over 100\\u00baF, or redness or pain at th...","ADVERSE REACTIONS\\nThe most common adverse reactions (incidence \\u2265 15%) are chills, fatigue, fever, back pain, nausea, joint\\nache, and headache. ( \\n6\\n)\\nTo report SUSPECTED ADVERSE REACTIONS, contact Dendreon Pharmaceuticals LLC at 1-\\n877-336-3736 or FDA at 1-800-FDA-1088 or \\nwww.fda.gov/medwatch\\n.\\nSee 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.\\nRevised: 7/2017\\nFULL PRESCRIBING INFORMATION: CONTENTS\\n*\\n1 INDICATIONS AND USAGE\\n2 DOSAGE AND ADMINISTRATION\\n2.1 Dose\\n2.2 Admi...","PROVENGE- sipuleucel-t injection \\n \\nDendreon Pharmaceuticals LLC\\n----------\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\nThese highlights do not include all the information needed to use PROVENGE \\n (sipuleucel-\\nT) safely and effectively. See full prescribing information for PROVENGE. \\nPROVENGE \\n (sipuleucel-T) \\nSuspension for Intravenous Infusion \\nInitial U.S. Approval: 2010\\nRECENT MAJOR CHANGES\\nDosage and Administration\\n     Administration ( \\n2.2\\n)\\n9/2014\\nWarnings and Precautions\\n     Acute Infusion R...","Control group received non-activated autologous peripheral blood mononuclear cells.\\nNausea\\n129 (21.5)\\n3 (0.5)\\n45 (14.9)\\n0 (0.0)\\nJoint ache\\n118 (19.6)\\n11 (1.8)\\n62 (20.5)\\n5 (1.7)\\nHeadache\\n109 (18.1)\\n4 (0.7)\\n20 (6.6)\\n0 (0.0)\\nCitrate toxicity\\n89 (14.8)\\n0 (0.0)\\n43 (14.2)\\n0 (0.0)\\nParesthesia\\n85 (14.1)\\n1 (0.2)\\n43 (14.2)\\n0 (0.0)\\nVomiting\\n80 (13.3)\\n2 (0.3)\\n23 (7.6)\\n0 (0.0)\\nAnemia\\n75 (12.5)\\n11 (1.8)\\n34 (11.2)\\n7 (2.3)\\nConstipation\\n74 (12.3)\\n1 (0.2)\\n40 (13.2)\\n3 (1.0)\\nPain\\n74 (12.3)\\n7 (1.2)\\n20 (6.6)\\n3 (1.0)\\n...","Relief from Allergies\\nfor a More Restful Night\\nReduces\\nSwelling of\\nNasal\\nPassages\\n1/2 FL OZ (15mL)\\nAFRIN NODRIP ALLERGY SINUS NIGHT  \\noxymetazoline hydrochloride spray\\nProduct Information\\nProduct Type\\nHUMAN OTC DRUG\\nItem Code (Source)\\nNDC:11523-0034\\nRoute of Administration\\nNASAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nOXYMETAZOLINE HYDROCHLORIDE\\n (UNII: K89MJ0S5VY) \\n(OXYMETAZOLINE\\n- UNII:8VLN5B44ZY)\\nOXYMETAZOLINE\\nHYDROCHLORIDE\\n0.5 mg\\n in 1 mL\\nInactive Ingredien...","CSF, consisting of prostatic acid phosphatase (PAP), an antigen expressed in prostate\\ncancer tissue, linked to granulocyte-macrophage colony-stimulating factor (GM-CSF), an\\nimmune cell activator. Each dose of PROVENGE contains a minimum of 50 million\\nautologous CD54 \\n cells activated with PAP-GM-CSF, suspended in 250 mL of Lactated\\nRinger&#x27;s Injection, USP.\\nThe active components of PROVENGE are autologous APCs and PAP-GM-CSF. During\\nculture, the recombinant antigen can bind to and be processed by..."]],["color",["#0a980a","#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e","#0a980a","#0a980a","#0a980a","#ba0e0e","#0a980a","#0a980a","#ba0e0e","#ba0e0e","#0a980a","#0a980a","#ba0e0e","#0a980a","#ba0e0e","#ba0e0e","#ba0e0e","#0a980a","#0a980a"]]]}}},"view":{"type":"object","name":"CDSView","id":"p1825","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1826"}}},"glyph":{"type":"object","name":"Scatter","id":"p1821","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.7},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.7}}},"nonselection_glyph":{"type":"object","name":"Scatter","id":"p1822","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.1},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.1},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"Scatter","id":"p1823","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.2},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.2}}}}},{"type":"object","name":"GlyphRenderer","id":"p1839","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p1830","attributes":{"selected":{"type":"object","name":"Selection","id":"p1831","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1832"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"eC2aQcdnk0GgzJNBuiKaQST4n0Go+LNBtr6jQXzzr0EBubRBsc6vQeqmq0E1lqhBUV+eQbqhpkE3PaxB/XKjQT5JoEGYyrdBKBupQWCIsEHxpqtByIixQS0GqUEPH6RB"},"shape":[24],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"a0qCQKedf0BZ0UpAxidSQAqaKkDwl6BAg1OKQCZYkECOi79Al7HRQAuEv0BSr9dAOA2qQIK3q0Co6KlAl1DEQARV2kBLWIlA00qQQFttd0DeT1lA5eY4QM6vHkCrsktA"},"shape":[24],"dtype":"float32","order":"little"}]]}}},"view":{"type":"object","name":"CDSView","id":"p1840","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1841"}}},"glyph":{"type":"object","name":"Scatter","id":"p1836","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"value","value":"grey"},"line_alpha":{"type":"value","value":0.2},"fill_color":{"type":"value","value":"grey"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"value","value":"grey"},"hatch_alpha":{"type":"value","value":0.2}}},"nonselection_glyph":{"type":"object","name":"Scatter","id":"p1837","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"value","value":"grey"},"line_alpha":{"type":"value","value":0.1},"fill_color":{"type":"value","value":"grey"},"fill_alpha":{"type":"value","value":0.1},"hatch_color":{"type":"value","value":"grey"},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"Scatter","id":"p1838","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"value","value":"grey"},"line_alpha":{"type":"value","value":0.2},"fill_color":{"type":"value","value":"grey"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"value","value":"grey"},"hatch_alpha":{"type":"value","value":0.2}}}}}],"toolbar":{"type":"object","name":"Toolbar","id":"p1793","attributes":{"logo":"grey","tools":[{"type":"object","name":"PanTool","id":"p1808"},{"type":"object","name":"WheelZoomTool","id":"p1809","attributes":{"renderers":"auto"}},{"type":"object","name":"BoxZoomTool","id":"p1810","attributes":{"overlay":{"type":"object","name":"BoxAnnotation","id":"p1811","attributes":{"syncable":false,"level":"overlay","visible":false,"left":{"type":"number","value":"nan"},"right":{"type":"number","value":"nan"},"top":{"type":"number","value":"nan"},"bottom":{"type":"number","value":"nan"},"left_units":"canvas","right_units":"canvas","top_units":"canvas","bottom_units":"canvas","line_color":"black","line_alpha":1.0,"line_width":2,"line_dash":[4,4],"fill_color":"lightgrey","fill_alpha":0.5}}}},{"type":"object","name":"ResetTool","id":"p1816"},{"type":"object","name":"SaveTool","id":"p1817"},{"type":"object","name":"HoverTool","id":"p1784","attributes":{"renderers":[{"id":"p1824"}],"tooltips":"\\n    &lt;div style=\\"width:400px;\\"&gt;\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\n    &lt;b&gt;Question:&lt;/b&gt; @questions &lt;br&gt;\\n    &lt;b&gt;agent Answer:&lt;/b&gt; @agent_answer &lt;br&gt;\\n    &lt;b&gt;Reference Answer:&lt;/b&gt; @reference_answer &lt;br&gt;\\n    &lt;b&gt;Correctness:&lt;/b&gt; @correctness &lt;br&gt;\\n    &lt;b&gt;Content:&lt;/b&gt; @content\\n    &lt;/div&gt;\\n    "}}]}},"left":[{"type":"object","name":"LinearAxis","id":"p1803","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p1804","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p1805"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1806"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"below":[{"type":"object","name":"LinearAxis","id":"p1798","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p1799","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p1800"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1801"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"center":[{"type":"object","name":"Grid","id":"p1802","attributes":{"axis":{"id":"p1798"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Grid","id":"p1807","attributes":{"dimension":1,"axis":{"id":"p1803"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Legend","id":"p1827","attributes":{"title":"Question Correctness","title_text_color":"#B1B1B1","title_text_font_style":"bold","border_line_alpha":0,"background_fill_color":"#111516","background_fill_alpha":0.5,"label_text_color":"#E0E0E0","label_text_font":"Helvetica","label_text_font_size":"1.025em","label_standoff":8,"glyph_width":15,"spacing":8,"items":[{"type":"object","name":"LegendItem","id":"p1828","attributes":{"label":{"type":"value","value":"False"},"renderers":[{"id":"p1824"}],"index":1}},{"type":"object","name":"LegendItem","id":"p1829","attributes":{"label":{"type":"value","value":"True"},"renderers":[{"id":"p1824"}],"index":0}}]}},{"type":"object","name":"LabelSet","id":"p1845","attributes":{"level":"glyph","source":{"type":"object","name":"ColumnDataSource","id":"p1842","attributes":{"selected":{"type":"object","name":"Selection","id":"p1843","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1844"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"95maQTf2q0E="},"shape":[2],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"tz5ZQNfypkA="},"shape":[2],"dtype":"float32","order":"little"}],["topic",["Nasal Decongestant","Prostate Cancer Immunotherapy"]]]}}},"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"text":{"type":"field","field":"topic"},"text_color":{"type":"value","value":"#B1B1B1"},"text_font_size":{"type":"value","value":"12pt"},"text_font_style":{"type":"value","value":"bold"},"text_align":{"type":"value","value":"center"}}}],"background_fill_color":"#14191B","border_fill_color":"#15191C"}}}}],"tabs_location":"below"}}]}}';
        const render_items = [{"docid":"3f75ef7e-eede-4b3b-80b8-9f9fa23c2c27","roots":{"p1850":"d32f9d71-0257-4b5f-8be8-241d5040c7fb"},"root_ids":["p1850"]}];
        root.Bokeh.embed.embed_items(docs_json, render_items);
        }
        if (root.Bokeh !== undefined) {
          embed_document(root);
        } else {
          let attempts = 0;
          const timer = setInterval(function(root) {
            if (root.Bokeh !== undefined) {
              clearInterval(timer);
              embed_document(root);
            } else {
              attempts++;
              if (attempts > 100) {
                clearInterval(timer);
                console.log("Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing");
              }
            }
          }, 10, root)
        }
      })(window);
    });
  };
  if (document.readyState != "loading") fn();
  else document.addEventListener("DOMContentLoaded", fn);
})();
    </script>

                <div id="d32f9d71-0257-4b5f-8be8-241d5040c7fb" data-root-id="p1850" style="display: contents;"></div>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">

                <div class="section-title">SELECTED METRICS</div>

                

            </div>
        </div>

        
    </div>
</div>



<script type="text/javascript">
    function opentab(evt, name) {
    // Declare all variables
    let i, tabcontent, tablinks;

    // Get all elements with class="tabcontent" and hide them
    tabcontent = document.getElementsByClassName("tabcontent");
    for (i = 0; i < tabcontent.length; i++) {
        tabcontent[i].style.display = "none";
    }

    // Get all elements with class="tablinks" and remove the class "active"
    tablinks = document.getElementsByClassName("tablinks");
    for (i = 0; i < tablinks.length; i++) {
        tablinks[i].className = tablinks[i].className.replace(" active", "");
    }

    // Show the current tab, and add an "active" class to the button that opened the tab
    document.getElementById(name).style.display = "block";
    evt.currentTarget.className += " active";
}
</script>
